Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd. – FDA 483, Mar 22, 2024
TIANJIN DARENTANG JINGWANHONG PHARMACEUTICAL CO., LTD. in Tianjin, China, was inspected and received five observations related to significant deficiencies in their manufacturing and quality control processes. The firm lacked adequate written procedures for production and process controls, failed to manage changes effectively, had insufficient laboratory controls including data review and impurity testing, and maintained unclean equipment. These issues indicate a lack of robust quality systems to ensure drug product identity, strength, quality, and purity.
- Inspection date
- March 22, 2024
- Product type
- drugs
ID · 7ee010d6-f98e-4201-8351-4cc71cae6bd1
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.